Should we use the angiotensin-converting enzyme inhibitors for the treatment of anti-VEGF-induced hypertension?

Ann Oncol. 2014 Aug;25(8):1669-70. doi: 10.1093/annonc/mdu197. Epub 2014 May 29.

Authors

G Emile¹, E Pujade-Lauraine², J Alexandre³

Affiliations

¹ Department of Medical Oncology, Paris Descartes University, School of Medicine, Cochin-Port Royal, Paris.
² Department of Medical Oncology, Paris Descartes University, School of Medicine, Hotel Dieu Hospital, Assistance Publique-Hopitaux de Paris, Paris, France.
³ Department of Medical Oncology, Paris Descartes University, School of Medicine, Cochin-Port Royal, Paris jerome.alexandre@cch.aphp.fr.

PMID: 24875797
DOI: 10.1093/annonc/mdu197

No abstract available

Publication types

Letter

MeSH terms

Amides / therapeutic use
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bevacizumab
Cohort Studies
Disease-Free Survival
Drug Substitution
Enalapril / therapeutic use
Female
Fumarates / therapeutic use
Humans
Hypertension / chemically induced*
Hypertension / drug therapy*
Hypertension / epidemiology
Ovarian Neoplasms / drug therapy*
Ovarian Neoplasms / pathology
Perindopril / therapeutic use
Protein Kinase Inhibitors / adverse effects
Recurrence
Vascular Endothelial Growth Factor A / antagonists & inhibitors*

Substances

Amides
Angiotensin-Converting Enzyme Inhibitors
Antibodies, Monoclonal, Humanized
Fumarates
Protein Kinase Inhibitors
VEGFA protein, human
Vascular Endothelial Growth Factor A
Bevacizumab
aliskiren
Enalapril
Perindopril